Effects of an angiotensin-converting enzyme inhibitor (captopril) on blood pressure in anephric subjects. 1980

A J Man in 't Veld, and I M Schicht, and F H Derkx, and J H de Bruyn, and M A Schalekamp

Randomised, double-blind cross-over trials were performed in seven anephric patients to determine the effect of the orally active angiotensin-converting enzyme inhibitor captopril on blood pressure in fluid-depleted and fluid-replete patients. Patients were given captopril, 100 mg orally, or placebo one hour after haemodialysis, when they were fluid depleted. Their mean (+/- SEM) supine blood pressure fell from 127 +/- 12/71 +/- 6 mm Hg before captopril to 106 +/- 13/54 +/- 4 mm Hg 24 hours after the drug, while on placebo it rose from 123 +/- 11/73 +/- 5 mm Hg to 134 +/- 10/82 +/- 8 mm Hg. All patients developed orthostatic hypotension after captopril. In the fluid-replete state, two days after haemodialysis, captopril had no effect on blood pressure. The plasma concentration of active renin was extremely low and did not rise after fluid withdrawal or captopril. Thus the hypotensive effect of captopril did not appear to depend on circulating renin concentrations. The concept of "renin-dependent" hypertension, which is responsive to captopril, as opposed to "volume-dependent" hypertension, which is not responsive to captopril, may therefore be invalid.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009392 Nephrectomy Excision of kidney. Heminephrectomy,Heminephrectomies,Nephrectomies
D011392 Proline A non-essential amino acid that is synthesized from GLUTAMIC ACID. It is an essential component of COLLAGEN and is important for proper functioning of joints and tendons. L-Proline,L Proline
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D012083 Renin A highly specific (Leu-Leu) endopeptidase that generates ANGIOTENSIN I from its precursor ANGIOTENSINOGEN, leading to a cascade of reactions which elevate BLOOD PRESSURE and increase sodium retention by the kidney in the RENIN-ANGIOTENSIN SYSTEM. The enzyme was formerly listed as EC 3.4.99.19. Angiotensin-Forming Enzyme,Angiotensinogenase,Big Renin,Cryorenin,Inactive Renin,Pre-Prorenin,Preprorenin,Prorenin,Angiotensin Forming Enzyme,Pre Prorenin,Renin, Big,Renin, Inactive
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D001826 Body Fluids Liquid components of living organisms. Body Fluid,Fluid, Body,Fluids, Body
D002216 Captopril A potent and specific inhibitor of PEPTIDYL-DIPEPTIDASE A. It blocks the conversion of ANGIOTENSIN I to ANGIOTENSIN II, a vasoconstrictor and important regulator of arterial blood pressure. Captopril acts to suppress the RENIN-ANGIOTENSIN SYSTEM and inhibits pressure responses to exogenous angiotensin. (S)-1-(3-Mercapto-2-methyl-1-oxopropyl)-L-proline,Capoten,Lopirin,SQ-14,225,SQ-14,534,SQ-14225,SQ-14534,SQ 14,225,SQ 14,534,SQ 14225,SQ 14534,SQ14,225,SQ14,534,SQ14225,SQ14534
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic

Related Publications

A J Man in 't Veld, and I M Schicht, and F H Derkx, and J H de Bruyn, and M A Schalekamp
April 1982, Nihon Jinzo Gakkai shi,
A J Man in 't Veld, and I M Schicht, and F H Derkx, and J H de Bruyn, and M A Schalekamp
January 1981, Acta medica Scandinavica. Supplementum,
A J Man in 't Veld, and I M Schicht, and F H Derkx, and J H de Bruyn, and M A Schalekamp
January 1989, Journal of ocular pharmacology,
A J Man in 't Veld, and I M Schicht, and F H Derkx, and J H de Bruyn, and M A Schalekamp
January 1986, Postgraduate medical journal,
A J Man in 't Veld, and I M Schicht, and F H Derkx, and J H de Bruyn, and M A Schalekamp
January 1982, Journal of cardiovascular pharmacology,
A J Man in 't Veld, and I M Schicht, and F H Derkx, and J H de Bruyn, and M A Schalekamp
August 1995, Immunopharmacology and immunotoxicology,
A J Man in 't Veld, and I M Schicht, and F H Derkx, and J H de Bruyn, and M A Schalekamp
February 1982, British journal of clinical pharmacology,
A J Man in 't Veld, and I M Schicht, and F H Derkx, and J H de Bruyn, and M A Schalekamp
January 1979, Hypertension (Dallas, Tex. : 1979),
A J Man in 't Veld, and I M Schicht, and F H Derkx, and J H de Bruyn, and M A Schalekamp
May 1992, The American journal of physiology,
A J Man in 't Veld, and I M Schicht, and F H Derkx, and J H de Bruyn, and M A Schalekamp
January 2016, European journal of pharmacology,
Copied contents to your clipboard!